On Friday, Xilio Therapeutics Inc (NASDAQ: XLO) opened lower -11.63% from the last session, before settling in for the closing price of $1.29. Price fluctuations for XLO have ranged from $0.50 to $1.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 59.04% at the time writing. With a float of $16.85 million, this company’s outstanding shares have now reached $43.96 million.
The firm has a total of 73 workers. Let’s measure their productivity. In terms of profitability, gross margin is 82.23%, operating margin of -852.23%, and the pretax margin is -834.92%.
Xilio Therapeutics Inc (XLO) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Xilio Therapeutics Inc is 58.43%, while institutional ownership is 15.72%. The most recent insider transaction that took place on Jan 02 ’25, was worth 6,841. In this transaction Chief Financial Officer of this company sold 6,954 shares at a rate of $0.98, taking the stock ownership to the 12,421 shares. Before that another transaction happened on Jan 02 ’25, when Company’s SVP, FINANCE AND ACCOUNTING sold 1,803 for $0.98, making the entire transaction worth $1,774. This insider now owns 3,197 shares in total.
Xilio Therapeutics Inc (XLO) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.65% during the next five years compared to -44.91% drop over the previous five years of trading.
Xilio Therapeutics Inc (NASDAQ: XLO) Trading Performance Indicators
Check out the current performance indicators for Xilio Therapeutics Inc (XLO). In the past quarter, the stock posted a quick ratio of 1.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.72, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Xilio Therapeutics Inc (XLO)
Analysing the last 5-days average volume posted by the [Xilio Therapeutics Inc, XLO], we can find that recorded value of 39.09 million was better than the volume posted last year of 6.83 million. As of the previous 9 days, the stock’s Stochastic %D was 62.93%. Additionally, its Average True Range was 0.17.
During the past 100 days, Xilio Therapeutics Inc’s (XLO) raw stochastic average was set at 47.66%, which indicates a significant increase from 47.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 351.50% in the past 14 days, which was higher than the 186.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9695, while its 200-day Moving Average is $0.9577. Now, the first resistance to watch is $1.2933. This is followed by the second major resistance level at $1.4467. The third major resistance level sits at $1.5933. If the price goes on to break the first support level at $0.9933, it is likely to go to the next support level at $0.8467. Should the price break the second support level, the third support level stands at $0.6933.
Xilio Therapeutics Inc (NASDAQ: XLO) Key Stats
There are currently 43,958K shares outstanding in the company with a market cap of 50.11 million. Presently, the company’s annual sales total 0 K according to its annual income of -76,400 K. Last quarter, the company’s sales amounted to 2,260 K and its income totaled -14,020 K.
